UroGen Pharma URGN Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's operating lease right-of-use asset amortization?
- UroGen Pharma (URGN) reported operating lease right-of-use asset amortization of $577K in Q1 2026.
- How has UroGen Pharma's operating lease right-of-use asset amortization changed year-over-year?
- UroGen Pharma's operating lease right-of-use asset amortization increased by 35.8% year-over-year, from $425K to $577K.
- What is the long-term trend for UroGen Pharma's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), UroGen Pharma's operating lease right-of-use asset amortization has grown at a 22.2% compound annual growth rate (CAGR), from $942K to $2.1M.